← Back to Clinical Trials
Recruiting NCT04109846

NCT04109846 Pregnancy and Developmental Outcomes After Transfer of Reportedly Aneuploid or Mosaic Embryos

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04109846
Status Recruiting
Phase
Sponsor Stanford University
Condition Aneuploidy
Study Type INTERVENTIONAL
Enrollment 300 participants
Start Date 2019-04-11
Primary Completion 2035-04

Eligibility & Interventions

Sex Female only
Min Age 18 Years
Max Age 55 Years
Study Type INTERVENTIONAL
Interventions
Non-euploid embryo transferEuploid Transfer

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 300 participants in total. It began in 2019-04-11 with a primary completion date of 2035-04.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

To determine how often embryos reported to be abnormal by preimplantation genetic testing result in liveborn infants. To evaluate whether the pregnancies that result from these embryos are higher risk for complications and whether the resulting babies have higher risk for health or developmental issues in the first five years after birth.

Eligibility Criteria

Inclusion Criteria: * Available aneuploid or mosaic embryos * No other acceptable embryos available * Willing to travel to Stanford for treatment * English language fluency Exclusion Criteria: * Use of international donor eggs or sperm not tested according to FDA guidelines. * Living outside the United States * Embryos with Triploidy are not eligible for transfer in this protocol

Contact & Investigator

Central Contact

Ronit Mazzoni, MS

✉ rmazzoni@stanford.edu

📞 408-688-9892

Principal Investigator

Ruth Lathi, MD

PRINCIPAL INVESTIGATOR

Stanford University

Frequently Asked Questions

Who can join the NCT04109846 clinical trial?

This trial is open to female participants only, aged 18 Years or older, up to 55 Years, studying Aneuploidy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04109846 currently recruiting?

Yes, NCT04109846 is actively recruiting participants. Contact the research team at rmazzoni@stanford.edu for enrollment information.

Where is the NCT04109846 trial being conducted?

This trial is being conducted at Sunnyvale, United States.

Who is sponsoring the NCT04109846 clinical trial?

NCT04109846 is sponsored by Stanford University. The principal investigator is Ruth Lathi, MD at Stanford University. The trial plans to enroll 300 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology